References 1. Yang H, Testa JR, Carbone M (2008) Mesothelioma epidemiology, carcino- genesis, and pathogenesis. Curr Treat Options Oncol 9: 147–57. Review. 2. Pass HI, Carbone M (2009) Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 21: 97–104. 3. Richards WG (2009) Recent advances in mesothelioma staging. Semin Thorac Cardiovasc Surg 21: 105–10. 4. Steele JP (2005) Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 19: 1041–52. Review. 5. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, et al. (2009) Oestrogen receptor b impacts on prognosis of human malignant mesothelioma. Cancer Res 69: 4598–604. 6. Ascenzi P, Bocedi A, Marino M (2006) Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med 27: 299–402. Review. 7. Pettersson K, Gustafsson JA (2001) Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 63: 165–92. 8. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, et al. (2001) A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A 98: 6330–5. 9. Erlandsson MC, Ohlsson C, Gustafsson JA, Carlsten H (2001) Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen- mediated effects on thymus. Immunology 103: 17–25. 10. Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, et al. (2006) Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci U S A 103: 2959–64. 11. Wang L, Andersson S, Warner M, Gustafsson JA (2001) Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc Natl Acad Sci U S A 98: 2792–6. 12. Marino M, Ascenzi P, Acconcia F (2006) S-palmitoylation modulates estrogen receptor alpha localization and functions. Steroids 71: 298–303. Review. 13. Marino M, Ascenzi P (2008) Membrane association of estrogen receptor alpha and beta influences 17beta-estradiol-mediated cancer cell proliferation. Steroids 73: 853–8. Review. 14. Levin ER (2003) Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 3: 309–17. Review. 15. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, et al. (2005) Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res 65: 10585–93. 16. Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, et al. (2006) Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci 1089: 194–200. 17. Filardo EJ, Quinn JA, Frackelton Jr. AR, Bland KI (2002) Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16: 70–84. 18. Kato S, Kitamoto T, Masuhiro Y, Yanagisawa J (1998) Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology 55: 5–10. Review. 19. Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama KI, et al. (2000) Molecular mechanism of a cross-talk between oestrogen and growth factor signaling pathways. Genes Cells 5: 593–601. Review. 20. Sanchez M, Picard N, Sauve´ K, Tremblay A (2010) Challenging estrogen receptor beta with phosphorylation. Trends Endocrinol Metab 21: 104–110. 21. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, et al. (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical ERb Function in Mesothelioma and molecular study with clinico-pathological correlations. Lung Cancer 51: 207–15. 22. Edwards JG, Swinson DE, Jones JL, Waller DA, O’Byrne KJ (2006) EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54: 399–407. 23. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, et al. (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 25: 2406–13. 24. Govindan R, Kratzke RA, Herndon JE, 2nd, Niehans GA, Vollmer R, et al. (2005) Gefitinib in patients with malignant mesothelioma: a phase II study. Clin Cancer Res 11: 2300–4. 25. Aguilar RC, Wendland B (2005) Endocytosis of membrane receptors: two pathways are better than one. Proc Natl Acad Sci U S A 102: 2679–80. 26. Couet J, Sargiacomo M, Lisanti MP (1997) Interaction of a receptor tyrosine kinase, EGFR, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272: 30429–38. 27. Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, et al. (2004) EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 112: 78–86. 28. Fukuoka M, Yano S, Giaccone G, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small- cell lung cancer. J Clin Oncol 21: 2237–46. 29. Arteaga CL (2003) ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284: 122–30. 30. Paez JG, Janne PA, Lee JC, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–500. 31. Cortese JF, Gowda AL, Wali A, Eliason JF, Pass HI, Everson RB (2006) Common EGFR mutations conferring sensitivity to gefitinib in lung adenocar- cinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118(2): 521–2. 32. Zhao C, Dahlman-Wright K, Gustafsson JA (2008) Estrogen receptor b: an overview and update. Nucl Recept Signal 6: 1–10. 33. Moggs JG, Orphanides G (2001) Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep 2: 775–81. 34. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, et al. (2009) Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 69: 6100–6. 35. Osborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11: 865–70. Review. 36. Arpino G, Wiechmann L, Osborne CK, Schiff R (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217–33. Review. 37. Fagan DH, Yee D (2008) Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13: 423–9. Review. 38. Smythe WR, Kaiser LR, Hwang HC, et al. (1994) Successful adenovirus- mediated gene transfer in an in vivo model of human malignant mesothelioma. The Annals of Thoracic Surgery 57: 1395–1401. 39. Bepler G, et al. (1988) Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 37: 158–171. 40. Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, et al. (2007) Induction of Tumorigenesis and Metastasis by the Murine Orthologue of Tumor Protein. Mol Cancer Res 5: 133–44. PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e14110